Holen Sie sich die Stockscreener-App
297.50
1.01%
-3.03
Handel nachbörslich:
297.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$300.53
Offen:
$301.05
24-Stunden-Volumen:
366.12K
Relative Volume:
1.08
Marktkapitalisierung:
$5.96B
Einnahmen:
$274.48M
Nettoeinkommen (Verlust:
$153.56M
KGV:
40.34
EPS:
7.3755
Netto-Cashflow:
$114.06M
1W Leistung:
+1.19%
1M Leistung:
-2.01%
6M Leistung:
+52.18%
1J Leistung:
+119.02%
1-Tages-Spanne:
$293.02
$304.97
1-Wochen-Bereich:
$293.02
$308.56
52-Wochen-Spanne:
$129.55
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
297.50 | 6.02B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | BofA Securities | Buy |
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Pharmaceuticals Inc (LGND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ligand Pharmaceuticals Inc (LGND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ligand Pharmaceuticals Inc (LGND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
LGND|Ligand Pharmaceuticals Inc|Price:300.530|Chg%:-1.620 - TradingKey
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Inc (LGND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals to report Q2 2026 results on August 6 - scanx.trade
Ligand Sets Aug. 6 Webcast for Second-Quarter Results - Stock Titan
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388 - Moomoo
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Citi Initiates Buy Rating on Ligand Pharmaceuticals (LGND) Follo - GuruFocus
LGND Reinstated by Citigroup -- Price Target Announced at $387 - GuruFocus
Ligand (LGND) Receives Buy Rating with $387 Target from Citi - GuruFocus
XOMA (XOMA) removes unsold securities after $200M shelf and merger - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Press Release: Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More Than 200 Biopharmaceutical Royalty Assets - Moomoo
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335 - Moomoo
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC : BENCHMARK RAISES TARGET PRICE TO $335 FROM $275 - Bitget
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings - Yahoo Finance
XOMA Royalty Corp (XOMA) holders tender shares in Ligand merger - Stock Titan
XOMA Royalty Corp (XOMA) investors cashed out at $39 per share in Ligand merger - Stock Titan
Benchmark raises Ligand Pharma stock price target to $335 on XOMA deal - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Ligand Pharma (LGND) - The Globe and Mail
RBC Capital raises Ligand Pharma stock price target on financing By Investing.com - Investing.com Canada
RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating - marketscreener.com
XOMA Royalty Corp (XOMA) director equity converted to $39 cash plus CVRs - Stock Titan
US53220KAJ7 Bond Profile — Key Metrics - TradingView
Ligand Pharmaceuticals Acquires XOMA Royalty for $739M, Doubling Portfolio to 200+ Biopharma Royalty Assets - Minichart
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase - marketscreener.com
Ligand Pharmaceuticals Amends and Extends $125 Million Revolver to 2028 With Citibank - TradingView
Ligand Pharmaceuticals (Nasdaq: LGND) closes $739M XOMA Royalty acquisition - Stock Titan
XOMA Royalty Announces Closing of Its Acquisition by Ligand - The Manila Times
Ligand completes acquisition of XOMA Royalty for $39 per share By Investing.com - Investing.com Canada
Ligand completes $739M acquisition of XOMA Royalty Corporation By Investing.com - Investing.com Canada
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets - marketscreener.com
Press Release: XOMA Royalty Announces Closing of Its Acquisition by Ligand - Moomoo
XOMA Royalty Corp (XOMA) legal chief’s stock and PSUs converted in Ligand merger - Stock Titan
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
3 Overlooked Stocks Positioned for the Next Market Rotation - Investing.com
Agenus Inc. announced that it expects to receive $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated - marketscreener.com
BofA raises Ligand Pharma stock price target on royalty growth By Investing.com - Investing.com South Africa
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):